The Japanese journal of surgery

, Volume 20, Issue 5, pp 553–558 | Cite as

Does H2-receptor antagonist alter the renal function of cyclosporine-treated kidney grafts?

  • Sumio Inoue
  • Hisayuki Sugimoto
  • Takeshi Nagao
  • Nobuo Akiyama
Original Articles


Histamine-type 2 antagonists (H2-blockers) as represented by cimentidine have been shown to adversely affect renal allograft function, particularly when coadministered with cyclosporine, currently a major immunosuppressant. To determine whether or not a newer and more powerful H2-blocker, famotidine, would produce similar adverse effects, we assessed seven cyclosporine-treated renal allograft recipients with regard to changes in their renal function on or off the H2-blocker over a one-week period. Neither the administration nor withdrawal of famotidine (20–40 mg/day) resulted in any significant changes in serum creatine, BUN, urine output or cyclosporine trough levels, suggesting that famotidine can be safely administered as an H2-blocker to cyclosporine-treated renal allograft recipients.

Key Words

histamine-type 2 antagonist kidney allograft cyclosporine famotidine 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Primack WA. Cimetidine and renal-allograft rejection. Lancet 1978; 1: 824–825.PubMedCrossRefGoogle Scholar
  2. 2.
    Zammit M, Toledo-Pereyra LH. Cimetidine for kidney transplantation: experimental observations. Surgery 1979; 86: 611–619.PubMedGoogle Scholar
  3. 3.
    Jarowenko MV, Van Buren CT, Kramer WG, Lorber, MI, Flechner SM, Kahan BD. Ranitidine, cimetidine, and the cyclosporine-treated recipient. Transplantation 1986; 42: 311–312.PubMedGoogle Scholar
  4. 4.
    Pachon J, Lorber MI, Bia MJ. Effects of H2-receptor antagonists on renal function in cyclosporine-treated renal transplant patients. Transplantation 1989; 47: 254–259.PubMedGoogle Scholar
  5. 5.
    Finklestein W, Isselbacher KJ. Drug therapy: cimetidine. N Engl J Med 1978; 229: 992–996.Google Scholar
  6. 6.
    Avella J, Madsen JE, Binder HJ, Askenase PW. Effect of histamine H2-receptor antagonists on delayed hypersensitivity. Lancet 1978; 25: 624–626.CrossRefGoogle Scholar
  7. 7.
    Zapata-Sirvent RL, Narrod JA, Hansbrough JF. Restoration of delayed hypersensitivity in mice receiving immunosuppressive drugs by cimetidine. transplantation 1985; 39: 449–450.PubMedGoogle Scholar
  8. 8.
    Kumar A, Cleveland RP. Immunoregulatory effects of cimetidine: inhibition of suppressor cell effector functionin vivo. Immunopharm Immunotoxicol 1988; 10: 327–332.Google Scholar
  9. 9.
    Gifford RRM, Tilberg AF. Cimetidine reduces cyclosporine inhibition of interleukin-2 production. J Surg Res 1989; 45: 276–280.CrossRefGoogle Scholar
  10. 10.
    Somogyi A, Gugler R. Drug interactions with cimetidine. Clin Pharmacokinet 1982; 7: 23–41.PubMedCrossRefGoogle Scholar
  11. 11.
    Speeg KV Jr, Patwardhan RV, Avant GR, Mitchell MC, Schenker S. Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studiedin vivo andin vitro in rodents. Gastroenterology 1982; 82: 89–96.PubMedGoogle Scholar
  12. 12.
    Castelao AM, Sabate I, Grino JM, Gil-Vernet S, Andres E, Sabater R, Alsina J. Cyclosporin-drug interactions. Transplant Proc 1988; 20 (Suppl. 6): 66–69.PubMedGoogle Scholar
  13. 13.
    Psanen M, Arvela P, Pellkonen O, Sotaniemi E, Klotz U. Effect of five structurally diverse H2-receptor antagonists on drug metabolism. Biochem Pharmac 1986; 35: 4457–4461.CrossRefGoogle Scholar
  14. 14.
    Imai Y, Inada M, Tamura S, Noda S, Kawata S, Minami Y, Tarui S. Inhibition of famotidine with rat liver microsomes, a study showing less inhibition of drug metabolism than with cimetidine. Pharmacol Res Commun 1986; 18: 629–638.PubMedCrossRefGoogle Scholar
  15. 15.
    Takagi T, Takeda M, Maeno H. Arch Int Pharmacoldyn Ther 1982; 256: 49–58.Google Scholar
  16. 16.
    Ohishi T, Sakiyama Y, Matsumoto S. Enhancement of the antibody response of human peripheral-blood mononuclear cells to sheep red-blood cells by the histamine H2-receptor antagonist famotidine. Igaku-no-ayumi 1988; 144: 581–582. (in Japanese with English Abst.)Google Scholar
  17. 17.
    Charpentier B, Fries D. Cimetidine and renal allograft rejection. Lancet 1978; 1: 1265.PubMedCrossRefGoogle Scholar
  18. 18.
    Garvin PJ, Carney K, Casteneda M, Codd JEJ. Peptic ulcer disease following transplantation: the role of cimetidine. Amer J Surg 1982; 144: 545–548.PubMedCrossRefGoogle Scholar
  19. 19.
    Beveridge T. Pharmacokinetics and metabolism of cyclosporin A. In White DJG ed. Cyclosporin A. Amsterdam, Elsevier Biomedical Press, 1982: 45–75.Google Scholar
  20. 20.
    D'souza MJ, Pollock SH, Solomon HM. Cyclosporin-cimetidine interaction. Drug Metab Dispos 1988; 16: 57–59.PubMedGoogle Scholar

Copyright information

© The Japan Surgical Society 1990

Authors and Affiliations

  • Sumio Inoue
    • 1
  • Hisayuki Sugimoto
    • 1
  • Takeshi Nagao
    • 1
  • Nobuo Akiyama
    • 1
  1. 1.The Department of Organ Transplantation, Institute of Medical ScienceThe University of TokyoTokyoJapan

Personalised recommendations